Phase IV Randomized Study Of Two Dose Levels Of Targretin Capsules In Patients With Refractory Cutaneous T-Cell Lymphoma.
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Bexarotene (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd; Valeant Pharmaceuticals International
- 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 27 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.